Ontology highlight
ABSTRACT:
SUBMITTER: Mesa R
PROVIDER: S-EPMC5215488 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
Mesa Ruben R Vannucchi Alessandro M AM Yacoub Abdulraheem A Zachee Pierre P Garg Mamta M Lyons Roger R Koschmieder Steffen S Rinaldi Ciro C Byrne Jennifer J Hasan Yasmin Y Passamonti Francesco F Verstovsek Srdan S Hunter Deborah D Jones Mark M MM Zhen Huiling H Habr Dany D Martino Bruno B
British journal of haematology 20161108 1
The randomized, double-blind, double-dummy, phase 3b RELIEF trial evaluated polycythaemia vera (PV)-related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported PV-related symptoms. Patients were randomized 1:1 to ruxolitinib 10 mg BID (n = 54) or hydroxycarbamide (prerandomization dose/schedule; n = 56); crossover to ruxolitinib was permitted after Week 16. The primary endpoint, ≥50% improvement from baseline in myeloprolife ...[more]